Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?
Approximately 30% of the worldwide population has at least one risk factor for liver disease. Identifying advanced liver disease before the occurrence of complications remains a difficult challenge in clinical practice, where diagnosis comes too late for many patients, at the time of liver decompens...
Main Authors: | Clémence M. Canivet, Jérôme Boursier |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/13/1/91 |
Similar Items
-
A Noninvasive Scoring System for Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease
by: Moniyka Sachar, et al.
Published: (2022-01-01) -
Noninvasive assessment of nonalcoholic fatty liver disease
by: Gajanan A Rodge, et al.
Published: (2021-01-01) -
The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study
by: Elfrid Christine Smith Sandvik, et al.
Published: (2022-08-01) -
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
by: Tina Reinson, et al.
Published: (2023-02-01) -
The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease
by: A. S. Kuznetsova, et al.
Published: (2023-01-01)